Victory Capital Management
TRIL

Victory Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Victory Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-290,571
Closed -$2.09M – 1874
2018
Q1 		$2.09M Buy
290,571
+71,600
+33% +$543K ﹤0.01% 1059
2017
Q4 		$1.6M Buy
218,971
+72,950
+50% +$604K ﹤0.01% 1105
2017
Q3 		$752K Sell
146,021
-550
-0.4% -$2.58K ﹤0.01% 1273
2017
Q2 		$645K Buy
146,571
+68,970
+89% +$382K ﹤0.01% 1262
2017
Q1 		$479K Buy
77,601
+22,171
+40% +$130K ﹤0.01% 1315
2016
Q4 		$313K Buy
+55,430
New +$552K ﹤0.01% 1337

Other funds holding TRIL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management's TRIL Position: Q2 2018 in Review

Victory Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2018, closing a stake of 290,571 shares — an estimated $2.09M sold.

Victory Capital Management first reported a position in TRIL in Q4 2016 and held it in 6 quarters. The position peaked at $2.09M in Q1 2018. 29 funds tracked by Wall St. Rank hold TRIL as of Q2 2018.

  • Victory Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q2 2018 after selling out during the quarter.
  • Victory Capital Management sold 290,571 Trillium Therapeutics Inc. shares in Q2 2018, an estimated $2.09M.
  • Victory Capital Management first reported a position in Trillium Therapeutics Inc. in Q4 2016 and held it in 6 quarters.
  • Victory Capital Management's Trillium Therapeutics Inc. position peaked at $2.09M in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2018.

Based on Victory Capital Management's 13F filing for Q2 2018, filed 2 Aug 2018.